In a report issued on October 31, Cory Kasimov from J.P. Morgan maintained a Buy rating on SAGE Therapeutics (SAGE). The company’s shares closed on Thursday at $137.55.
According to TipRanks.com, Kasimov is a 2-star analyst with an average return of 0.0% and a 37.8% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Jounce Therapeutics Inc, and Vertex Pharmaceuticals.
Currently, the analyst consensus on SAGE Therapeutics is a Strong Buy with an average price target of $220.25, a 60.1% upside from current levels. In a report issued on October 17, Oppenheimer also initiated coverage with a Buy rating on the stock with a $170 price target.
.
See today’s analyst top recommended stocks >>
Based on SAGE Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $90 million and GAAP net loss of $16.98 million. In comparison, last year the company had a GAAP net loss of $73.72 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.